Results 81 to 90 of about 1,925 (192)

Uneven Implementation of Nirsevimab Prophylaxis Resulted in Non-Uniform Reductions in RSV-Related Hospitalizations in Italy

Background/Objectives: Respiratory syncytial virus (RSV) bronchiolitis remains a leading cause of hospitalization in infants. In the 2024–2025 season, passive newborn immunization with nirsevimab, a long-acting anti-RSV monoclonal antibody, was ...
Enrico Valletta, Anthea Mariani, Claudio Cafagno, Désirée Caselli, Francesco Accomando, Claudia Rossini, Martina Fornaro, Giulia Marozzi, Melodie O. Aricò, Daniela Trotta, Letizia Lorusso, Maurizio Aricò   +11 more
core   +1 more source

Estimating the economically justifiable price of nirsevimab versus standard of practice for the prevention of respiratory syncytial virus infections in neonates and infants in Spain: a cost–utility modelling study

BMJ Public Health
Introduction Respiratory syncytial virus (RSV) causes great morbidity and mortality among newborns. Nirsevimab represents a prophylactic alternative used in Spain for a universal prophylaxis strategy of all infants.
Miguel Angel Casado, Ruth Gil-Prieto, Jaime Pérez-Martín, Ariadna Díaz Aguiló, Samira Soudani, Leticia Platero-Alonso, Juan Luis López-Belmonte, Alberto de la Cuadra-Grande, Javier Álvarez Aldean   +8 more
doaj   +1 more source

Nirsevimab Effectiveness Against Intensive Care Unit Admission for Respiratory Syncytial Virus in Infants - 24 States, December 2024-April 2025

Respiratory syncytial virus (RSV) is a leading cause of intensive care unit (ICU) admission and respiratory failure among infants (children aged \u3c year) in the United States.
Orzel-Lockwood, Amber O., Schuster, Jennifer E., al, et, Zerr, Danielle M., Gertz, Shira J., Irby, Katherine, Payne, Amanda B., Calixte, Jemima M., Chiotos, Kathleen, Crandall, Hillary, Nofziger, Ryan A., Hume, Janet R., Simeone, Regina M., Kamidani, Satoshi, Shein, Steven L., Halasa, Natasha B., Maddux, Aline B., Michelson, Kelly N., Newhams, Margaret M., Bhumbra, Samina S., Chauhan, Jigar C., Guzman-Cottrill, Judith A., Coates, Bria M., Staat, Mary Allen, Kong, Michele, Martin, Lora M., Bradford, Tamara T., Cameron, Melissa A., Zambrano, Laura D.   +28 more
core   +1 more source

Respiratory Syncytial Virus Disease Burden and Nirsevimab Effectiveness in Young Children From 2023-2024

Importance: During the 2023-2024 respiratory syncytial virus (RSV) season in the United States, 2 new RSV prevention products were recommended to protect infants in their first RSV season: nirsevimab and Pfizer\u27s maternal RSV vaccine.
Boom, Julie A, Toepfer, Ariana P, Goldstein, Leah, Paden, Clinton, Clopper, Benjamin R, Thornburg, Natalie J, Dawood, Fatimah S, Sahni, Leila C, Englund, Janet A, Atherton, Lydia, Schlaudecker, Elizabeth P, Schuster, Jennifer E, Michaels, Marian G, Aggarwal, Megha, Stewart, Laura S, Halasa, Natasha B, Staat, Mary A, Piedra, Pedro A, Selvarangan, Rangaraj, Roychoudhury, Pavitra, Derado, Gordana, McKeever, Erin R, McMorrow, Meredith L, Klein, Eileen J, Tannis, Ayzsa, Moline, Heidi L, Williams, John V, Weinberg, Geoffrey A, Szilagyi, Peter G, Kalman, Casey, New Vaccine Surveillance Network Collaborators   +30 more
core   +1 more source

Assessment of effectiveness and impact of universal prophylaxis with nirsevimab for prevention of hospitalizations due to respiratory syncytial virus in infants. The NIRSE-GAL study protocol

Human Vaccines & Immunotherapeutics
Nirsevimab has been recently licensed for universal RSV prophylaxis in infants. NIRSE-GAL is a three-year population-based study initiated in Galicia in September 2023.
Narmeen Mallah, Sonia Ares-Gómez, Jacobo Pardo-Seco, Alberto Malvar-Pintos, María-Isolina Santiago-Pérez, Olaia Pérez-Martínez, María-Teresa Otero-Barrós, Nuria Suárez-Gaiche, Rolf Kramer, Jing Jin, Leticia Platero-Alonso, Rosa-María Alvárez-Gil, Olga-María Ces-Ozores, Victoria Nartallo-Penas, Susana Mirás-Carballal, Marta Piñeiro-Sotelo, Juan-Manuel González-Pérez, Carmen Rodríguez-Tenreiro, Irene Rivero-Calle, Antonio Salas, Carmen Durán-Parrondo, Federico Martinón-Torres   +21 more
doaj   +1 more source

Efficacy and safety of monoclonal antibodies against respiratory syncytial virus disease in premature infants: a systematic review and network meta-analysis

Frontiers in Pediatrics
ObjectiveRespiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection (LRTI) in infants and young children, which may progress to bronchiolitis, pneumonia, and other severe respiratory complications.
Shunli Liu, Shunli Liu, Yan Wang, Yan Wang, Yang Cao, Yang Cao, Huiling Song, Huiling Song, Zhiqing Tian, Zhiqing Tian, Xue Li, Xue Li, Lan Huang, Lan Huang   +13 more
doaj   +1 more source

Nirsevimab Administration and RSV Hospitalization in the 2024-2025 Season

JAMA Network Open
This cohort study examines rates of hospitalization associated with respiratory syncytial virus (RSV) among infants by nirsevimab administration during the 2024-2025 season.
Pelletier, Jonathan H., Rush, Sarah Z., Robinette, Eric, Maholtz, Danielle E., Bigham, Michael T., Forbes, Michael L., Shein, Steven L., Karsies, Todd J., Horvat, Christopher M.   +8 more
openaire   +2 more sources

CDC\u2019s Vaccines for Children Program Addendum : Special Considerations for Nirsevimab

Nirsevimab is an FDA-licensed monoclonal antibody that provides passive immunity against RSV-associated infection. On August 3, 2023, the Advisory Committee on Immunization Practices (ACIP) voted to recommend nirsevimab as an immunization for all infants

core  

Genotypic and phenotypic characterisation of respiratory syncytial virus after nirsevimab breakthrough infections: a large, multicentre, observational, real-world study

International audienceBackgroundNirsevimab, a long-acting monoclonal antibody, has been approved for the prevention of respiratory syncytial virus (RSV) infection in infants.
Morton Fauche, Claire, Derman, Boris, Azemar, Benjamin, Guinard, Jérome, Yab, Emilie, Reslan, Alawyia, Mouna, Lina, Gras-Le Guen, Christele, Flechelles, Olivier, Dossou, Nefert Candace, Brichler, Ségolène, Jatteau, Pierre, Rahou, Yannis, Calvez, Vincent, dos Santos, Georges, Gabassi, Audrey, Fourati, Slim, Plantier, Jean-Christophe, Prot, Matthieu, Legros, Romain, Moreau, Frédérique, Cantais, Aymeric, Bouthry, Elise, Crémadés, Agathe, Gault, Elyanne, Francois, Catherine, Cocherie, Théophile, Boussetta-Charfi, Oulfa, da Silva, Kévin, Schnuriger, Aurélie, Salmona, Maud, Thibault, Vincent, Zemali, Nael, Gaymard, Alexandre, Mnemosyme, Nicolas, Mortamet, Guillaume, Pronier, Charlotte, Bal, Antonin, Bret, Laurent, Avettand-Fenoel, Véronique, Gaitan, Léa, Pawlotsky, Jean-Miichel, Soulié, Cathia, Gallais, Floriane, Bourlet, Thomas, Carcenac, Romain, Simon-Loriere, Etienne, Schwartz, Olivier, Le Goff, Jérôme, Natella, Pierre-André, Staes, Laetitia, Handala, Lynda, Lemoine, Frédéric, Fagour, Laurence, Moisan, Alice, Rogez, Sylvie, Lemoine, Frédérique, Fofana, Djeneba, Ly, Arnaud, Tournegros, Caroline, Rodallec, Audreay, Rachik Abdeljalil, Senhaji, Henry, Steven, Hartard, Cédric, Castain, Louise, Claudet, Isabelle, Audureau, Etienne, Ferrani, Salim, Vallet, Sophie, Castelain, Sandrine, Jeziorski, Eric, Lefeuvre, Caroline, Buchrieser, Julian, Pillet, Sylvie, Veyrenche, Nicolas, Henquell, Cecile, Burrel, Sonia, Mafi, Sarah, Lesne, Fabien, Warnakulasuriya, Fairly, Pilorgé, Léa, Guillaume, Clémence, Jaffar, Marie-Christine, de Pontual, Loic, Bonacorsi, Stéphane, Petat, Hortense, Domitien, Léa, Ader, Mohamed, Regueme, Alexandre, Teyssou, Elisa, Bourret, Jérome, Ouldali, Naim, Foulongne, Vincent, Berreira Ibraim, Samar, Marie, Victoria, Rames, Cinthia, Pawlotsky, Jean-Michel, Tremeaux, Pauline, Enouf, Vincent, Schapira, Anne-Julie, Henry, Amandine, Zekre, Franck, Leveque, Nicolas, Heaugwane, Diana, Rodriguez, Christophe, Zavaoarisaina, Zakasoa-Mbololona, Gaudy-Graffin, Catherine, Vellas, Camille, Perrier, Marine, Néré, Marie-Laure, Vabret, Astrid, Chenafi-Adham, Sara, Le Hingrat, Quentin, Ogoudjobi, Stanislas, Solis, Morgane, Alidjinou, Kazali, Engelmann, Ilka, Rameix-Welti, Marie-Anne, Habib, Mohamed, Marot, Stéphane, Mchantaf, Gilbert, de Oliveira, Anthony, Faisant, Anne, Imbert-Marcille, Berthe-Marie, Gleizes, Eva, Donati, Flora, Deback, Claire, Deroche, Luc, Jeyarajah, Banujaa, Pucelle, Mélanie, Sourice, Justine, Jaffar-Bandjee, Marie-Christine, Soulier, Alexandre, Seng, Sarah, Reslan, Alawiya, Larrat, Sylvie, Souply, Laurent, Pennisi, Alessandra, Kombou, Jose, Aupiais, Camille, Pargny, Vincent, Mirand, Audrey, Cappy, Pierre, Chollet, Lionel, Chauvire-Drouard, Anne, Gardan, Vincent, Bécourt, Arnaud, Casalegno, Jean-Sébastien, Stephan, Valentin   +148 more
core   +1 more source

Estimated Effectiveness of Nirsevimab Against Respiratory Syncytial Virus

JAMA Network Open
IMPORTANCENirsevimab, a long-acting monoclonal antibody, demonstrated efficacy against respiratory syncytial virus (RSV)–associated lower respiratory tract infections (LRTI) in clinical trials. Postlicensure monitoring is essential to confirm these benefits in clinical settings.OBJECTIVETo estimate the effectiveness of nirsevimab against medically ...
Xu, Hanmeng, Aparicio, Camila, Wats, Aanchal, Araujo, Barbara L., Pitzer, Virginia E., Warren, Joshua L., Shapiro, Eugene D., Niccolai, Linda M., Weinberger, Daniel M., Oliveira, Carlos R.   +9 more
openaire   +2 more sources